Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) announced that Synjardy® (empagliflozin/metformin hydrochloride) tablets are now ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Lilly's (LLY) Risk/Reward Looks Good Ahead of Q3 Report - BMOOctober 16, 2015 10:45 AM New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. PharmaciesOctober 14, 2015 8:30 AM Eli Lilly (LLY), Incyte (INCY) Announced Baricitinib Demonstrates Superiority to Adalimumab in Phase 3 RA StudyOctober 14, 2015 6:47 AM